KRAS and colorectal carcinoma: A meta-analysis of four randomized controlled trials analyzing resectability in patients with wild-type KRAS CRC whose metastatic lesions are limited in the liver reported that the addition of cetuximab or panitumumab to chemotherapy significantly increased the R0 resection rate from 11% to 18% (relative risk (RR), 1.59; p = 0.04) and ORR (RR, 1.67; p = 0.0001) comparing to chemotherapy alone [18].